论文部分内容阅读
糖皮质激素抵抗型病例的出现 ,对于以激素为主要治疗药物的疾病 (如肾病综合征 )而言是一个严重的挑战 ,鉴于糖皮质激素主要通过结合糖皮质激素受体方能发挥生物学和治疗效应 ,这方面的研究一直是颇受关注的焦点。晚近的研究显示糖皮质激素受体 β(GRβ)可能是一种潜在的内源性糖皮质激素效应的拮抗因子 ,为揭示糖皮质激素抵抗现象的发生提供了一种新的研究思路。本文就糖皮质激素受体亚型 (GRα和GRβ)与糖皮质激素效应、尤其是与糖皮质激素抵抗之间关系的研究进展做一综述。
The emergence of glucocorticoid-resistant cases is a serious challenge for diseases where hormones are the primarystay of treatment, such as nephrotic syndrome, given that glucocorticoids exert both biological and therapeutic functions by binding glucocorticoid receptors Therapeutic effects, research in this area has been the focus of much attention. Recent studies have shown that glucocorticoid receptor β (GRβ) may be a potential antagonist of endogenous glucocorticoid effect, providing a new research idea to reveal the occurrence of glucocorticoid resistance. This article reviews the research progress of the relationship between glucocorticoid receptor subtypes (GRα and GRβ) and glucocorticoid effect, especially glucocorticoid resistance.